Navigation Links
AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
Date:8/12/2008

the Dresden Technical University. In 1995, he received the Galenus-von-Pergamon prize for having developed alkylphospholipids as a new class of anti-tumor agents. Prof. Engel is the author of more than 250 scientific articles, several books and he applied for more than 100 patent applications.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
2. AEterna Zentaris Sells Quebec City Building for $7.1 million
3. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
4. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
5. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
6. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
7. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
8. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Announces Changes to its Management Team
11. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014   Sequenom, Inc. (NASDAQ: ... provides innovative genetic analysis solutions, and Mayo Medical ... services in the United States , ... patents and applications. "We have great appreciation ... care, and we welcome the opportunity to partner with ...
(Date:7/29/2014)... Human Longevity, Inc. (HLI), a genomics and ... the healthy, high performance human life span, today announced ... expert in machine learning and machine translation as the ... Google where he was Distinguished Research Scientist and the ... HLI Co-Founder and CEO, J. Craig Venter , ...
(Date:7/29/2014)... particle be separated from its properties? On July 29, ... results of the first Cheshire Cat experiment, separating a ... in Orange, CA, and Vienna University of Technology. , ... grin," thought Alice in Wonderland, "but a grin without ... saw in my life!" Alice,s surprise stems from her ...
(Date:7/29/2014)... 2014) Tough, ultralight foam of atom-thick sheets can ... chemical process invented at Rice University. , In ... nanoscale building, with floors and walls that reinforce each ... materials: floors and walls of graphene oxide that self-assemble ... , The researchers say the foam could find use ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4Tough foam from tiny sheets 2
... , , COLUMBIA, Md., Dec. 16 Martek ... for the fourth quarter and fiscal year ended October 31, 2009. ... $90.4 million in the fourth quarter of fiscal 2008. Net income ... quarter of fiscal 2009, a 5% increase compared with $10.5 million, ...
... , , LAS VEGAS, Dec. 16 Cord Blood America, Inc. ... company ( http://www.cordblood-america.com ) focused on bringing the life saving ... and internationally, said today that it has reduced its debt by ... of 2009 and total debt eliminated for the year now tops ...
... , , ... Inc. (Nasdaq: SQNM ), today announced the appointment of Dr. ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) , Kenneth F. Buechler, ... From 1988 to 1994, Dr. Buechler was Biosite,s director of chemistry. ...
Cached Biology Technology:Martek Announces Fourth Quarter and FY 2009 Financial Results 2Martek Announces Fourth Quarter and FY 2009 Financial Results 3Martek Announces Fourth Quarter and FY 2009 Financial Results 4Martek Announces Fourth Quarter and FY 2009 Financial Results 5Martek Announces Fourth Quarter and FY 2009 Financial Results 6Martek Announces Fourth Quarter and FY 2009 Financial Results 7Martek Announces Fourth Quarter and FY 2009 Financial Results 8Martek Announces Fourth Quarter and FY 2009 Financial Results 9Martek Announces Fourth Quarter and FY 2009 Financial Results 10Martek Announces Fourth Quarter and FY 2009 Financial Results 11Martek Announces Fourth Quarter and FY 2009 Financial Results 12Martek Announces Fourth Quarter and FY 2009 Financial Results 13Martek Announces Fourth Quarter and FY 2009 Financial Results 14Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3
(Date:7/29/2014)... fascinating journey to the edge of science, Clment Vidal ... The Beginning and the End: Does our universe have ... Are we alone in the universe? What is the ... Grounded in science and committed to philosophical rigor, the ... intelligent life is not an accident, but may well ...
(Date:7/29/2014)... comes to technology, healthcare is usually one of the last industries ... comes to wearables, healthcare is trying to move ahead of the ... and its wearable cousins is less than mature, these devices are ... in the hospital for a major procedure or for personal use ... mind, InformationWeek editor Rodney Brown set out to ...
(Date:7/29/2014)... personal genetics company, has received from the National ... for a two-year project to support the further ... for genetic discovery. , Specifically, the grant ... of web-based surveys to improve the company,s ability ... of survey tools to support the collection of ...
Breaking Biology News(10 mins):Book: 'The Beginning and the End' 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3
... found that the number of pests and disease outbreaks in ... The review "The consequences of Tree Pests and ... Southampton, Cambridge, Oxford and St Andrews is published today (15 ... shows that the experience of widespread death of trees, similar ...
... Clinic Lerner Research Institute have discovered recent genetic mutations ... of malaria annuallychanges that may render tens of millions ... infection. Peter A. Zimmerman, professor of international health, ... of Medicine, and David Serre, a scientific staff member ...
... , Nov. 14, 2013 Wake Forest Baptist Medical ... first-of-its-kind strategic affiliation agreement in the Triad with Cornerstone ... Cornerstone Health Enablement Strategic Solutions, LLC (CHESS). ... both partners for new models of health care delivery ...
Cached Biology News:Rising concerns over tree pests and diseases 2Vivax malaria may be evolving around natural defense 2Vivax malaria may be evolving around natural defense 3Wake Forest Baptist Medical Center and Cornerstone Health Care Join in Unique Affiliation 2Wake Forest Baptist Medical Center and Cornerstone Health Care Join in Unique Affiliation 3
... The Bio-Plex suspension array system, 100-240 V, ... for simultaneous quantitative analysis of up to ... microplate well. The suspension array is composed ... each of which may be conjugated with ...
...
... Disposable. Virgin, optically clear polystyrene with ... alphanumeric coordinates for cell counting. 100% ... is a new product number, created ... If showing no availability yet, please ...
... 100 IS System is a compact analysis system ... lasers, optics, fluidics, a controller, advanced digital signal ... compact lab analysis system includes the Luminex 100, ... has a DMF file at the FDA, and ...
Biology Products: